Alipogene tiparvovec

Active ingredient description

Alipogene tiparvovec contains the human lipoprotein lipase (LPL) gene variant LPLS447X in a vector. The human LPL gene variant LPLS447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle. Alipogene tiparvovec is injected as a one-time series into the muscle of the lower extremities where it is taken up by myocytes.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Alipogene tiparvovec
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX10

Medicines

Alipogene tiparvovec is the active ingredient of these drugs:

Drug
Countries

Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)

Unique ingredient identifier (UNII)

20OK4AFR4Y - ALIPOGENE TIPARVOVEC

CAS registry number

929881-05-0 - alipogene tiparvovec